Uploaded October 2019 | Updated September 2026, 1 day ago
Eugene Shippen, M.D.
Author, “The Testosterone Syndrome”
Interview Topic: Estrogen in Men
AMMG Interviewer: Dr. Derrick DeSilva, Jr.
Dr. Eugene Shippen has been in medical practice since 1973, primarily in Family Practice for the first 25 years, and Endocrinology focused on male and female hormonal problems due to aging and disease until the present. After publication of his book, “The Testosterone Syndrome” in 1998, the focus of his practice changed to aging Endocrinology with an emphasis on male and female hormonal evaluation and treatment. This lead to many opportunities for Dr. Shippen to lecture and provide tutorial seminars on these subjects both nationally and internationally.
At the Age Management Medicine Group Spring Conference in Miami, Florida Dr. Shippen spoke about Pearls and Pitfalls of Testosterone Boosting Modalities
Lecture Description: The primary reason for low testosterone in younger aging males, and for some older aging males as well, is low gonadotrophin output, particularly LH. Leydig cells decline with aging and persistently low gonadotrophins and some diseases, i.e., hemochromatosis, hypothyroidism, etc. If boosting methods fail, then primary hypogonadism is present and replacement modalities are required. Reasons for low gonadotrophins today may be related to xeno-estrogens in diet and environmental intake. Additionally, obesity with increased endogenous estrogens, drugs and poor health or co-morbid diseases add to the long list that requires investigation. In this regard, we can do much to change negative patterns, but along with these changes we can add great benefits through boosting testosterone through increasing gonadotrophins or giving them directly. In my experience, boosting should be the first diagnostic and treatment intervention before direct replacement of testosterone is initiated, particularly under the age of 65. The three most common methods are: (1) Through the use of SERMS, such as clomiphene or analogues; (2) Suppression of endogenous conversion of androgens into estrogens within the hypothalamus with reversible aromatase inhibitors like anastrozole or femara; and (3) hCG – Chorionic Gonadotrophin, a direct LH containing natural compound with a very long history of safe, effective uses. My discussion will cover the background literature and my long use of all three modalities and some observations on potential problems and benefits of these approaches. Some of the unique benefits are poorly known and, sadly, under-utilized. Questions and answers will be welcomed depending on time constraints.
Eugene Shippen, M.D.
Author, “The Testosterone Syndrome”
Interview Topic: Estrogen in Men
AMMG Interviewer: Dr. Derrick DeSilva, Jr.
Dr. Eugene Shippen has been in medical practice since 1973, primarily in Family Practice for the first 25 years, and Endocrinology focused on male and female hormonal problems due to aging and disease until the present. After publication of his book, “The Testosterone Syndrome” in 1998, the focus of his practice changed to aging Endocrinology with an emphasis on male and female hormonal evaluation and treatment. This lead to many opportunities for Dr. Shippen to lecture and provide tutorial seminars on these subjects both nationally and internationally.
At the Age Management Medicine Group Spring Conference in Miami, Florida Dr. Shippen spoke about Pearls and Pitfalls of Testosterone Boosting Modalities
Lecture Description: The primary reason for low testosterone in younger aging males, and for some older aging males as well, is low gonadotrophin output, particularly LH. Leydig cells decline with aging and persistently low gonadotrophins and some diseases, i.e., hemochromatosis, hypothyroidism, etc. If boosting methods fail, then primary hypogonadism is present and replacement modalities are required. Reasons for low gonadotrophins today may be related to xeno-estrogens in diet and environmental intake. Additionally, obesity with increased endogenous estrogens, drugs and poor health or co-morbid diseases add to the long list that requires investigation. In this regard, we can do much to change negative patterns, but along with these changes we can add great benefits through boosting testosterone through increasing gonadotrophins or giving them directly. In my experience, boosting should be the first diagnostic and treatment intervention before direct replacement of testosterone is initiated, particularly under the age of 65. The three most common methods are: (1) Through the use of SERMS, such as clomiphene or analogues; (2) Suppression of endogenous conversion of androgens into estrogens within the hypothalamus with reversible aromatase inhibitors like anastrozole or femara; and (3) hCG – Chorionic Gonadotrophin, a direct LH containing natural compound with a very long history of safe, effective uses. My discussion will cover the background literature and my long use of all three modalities and some observations on potential problems and benefits of these approaches. Some of the unique benefits are poorly known and, sadly, under-utilized. Questions and answers will be welcomed depending on time constraints.
